StephensM.L., & BallsM. (2006). LD50 testing of Botulinum toxin for use as a cosmetic. ALTEX23, Special Issue, 153–156.
2.
BallsM., & StephensM.L. (2006). Time for alternative action. Soap, Perfumery & CosmeticsFebruary, 32–33.
3.
PickettA. (2012). The botulinum toxin LD50 potency assay — Another chapter, another mystery. ATLA40, 221–223.
4.
Fernandex-SalasE., WangJ., MolinaY., NelsonJ.B., JackyB.P.S., & AokiK.R. (2012). Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One7, e49515.
5.
Allergan, Inc. (2011). Allergan receives FDA approval for first-of-its-kind, fully in vitro, cell-based assay for BOTOX® and BOTOX® Cosmetic (onabotulinum-toxinA). [Press release, 24.06.11]. Available at: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=587234 (Accessed 28.10.12).
6.
BurkeG.S. (1919). The occurrence of Bacillus botulinus in nature. Journal of Bacteriology4, 541–553.
7.
PiazzaT.M., BiehertD.S., DunningF.M., Berlowski-ZierB.M., ZeytinF.N., SamuelM.D., & TuckerW.C. (2011). In vitro detection and quantification of botulinum neurotoxin type E activity in avian blood. Applied & Environmental Microbiology77, 7815–7822.
8.
DunningF.M., RugeD.R., PiazzaT.M., StankerL.H., ZeytinF.N., & TuckerW.C. (2012). Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to fentomolar sensitivity. Applied & Environmental Microbiology78, 7687–7697.
9.
RugeD.R., DunningF.M., PiazzaT.M., MollesB.E., AdlerM., ZeytinF.N., & TuckerW.C. (2011). Detection of six serotypes of botulinum neurotoxin using fluorogenic reporters. Analytical Biochemistry411, 200–209.
10.
ICCVAM (2008). Report on the ICCVAM-NICEATM/ ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing, 36 pp. Research Triangle Park, NC, USA: National Institutes of Health. Available at: http://iccvam.niehs.nih.gov/docs/biologics-docs/BoNTwkshprept.pdf (Accessed 27.11.12).